Prelude Capital Management’s Chemours CC Stock Holding History

Prelude Capital Management’s Portfolio CC Stock Details CC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-65,000	Closed	-$2.08M	–	1608
2022 Q2	$2.08M	Buy	+65,000	New	+$2.39M	0.06%	286
2018 Q4	–	Sell	-17,800	Closed	-$702K	–	1800
2018 Q3	$702K	Buy	+17,800	New	+$779K	0.04%	442
2017 Q3	–	Sell	-500	Closed	-$19K	–	1645
2017 Q2	$19K	Buy	+500	New	+$19.7K	﹤0.01%	1267

Other funds holding CC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AWAM

Appian Way Asset Management New York $558M AUM 1.95% 1-Year Est. Return

Prelude Capital Management's CC Position: Q1 2025 in Review

Prelude Capital Management sold out of Chemours (CC) in Q1 2025, closing a stake of 147,727 shares — an estimated $2.5M sold.

Prelude Capital Management first reported a position in CC in Q3 2015 and held it in 25 quarters. The position peaked at $12.3M in Q2 2021. 419 funds tracked by Wall St. Rank hold CC as of Q1 2025.

Prelude Capital Management reported no remaining Chemours position as of Q1 2025 after selling out during the quarter.
Prelude Capital Management sold 147,727 Chemours shares in Q1 2025, an estimated $2.5M.
Prelude Capital Management first reported a position in Chemours in Q3 2015 and held it in 25 quarters.
Prelude Capital Management's Chemours position peaked at $12.3M in Q2 2021.
419 funds tracked by Wall St. Rank held Chemours as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.